{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'ARGX-113 treatment induces reductions in IgG levels, and there is a potential risk for', 'infections associated with the low IgG levels. As such, any infection will be considered AESI', 'in this trial. Further characterizing information will be collected in the eCRF, such as: location', 'of infection, relationship to underlying condition, medical history and concomitant medication,', 'reoccurence of previous infection, previous rescue therapy, any confirmatory procedure,', 'culture or urgent medical intervention.', '7.2.1.2. Reporting of Adverse Events and Serious Adverse Events', 'All AEs that occur during the trial from signature of the ICF until EoS are to be recorded on', 'the appropriate AE pages (either \"serious\\' or \"non-serious\\') in the eCRF. The Investigator', 'should complete all the details requested, including dates of onset, time of onset, stop date', '(when applicable), stop time (when applicable), severity, action taken, outcome, and', 'relationship to IMP, and to trial procedures. Each event should be recorded separately in the', 'eCRF.', 'All AEs spontaneously reported by the patient or reported in response to the open question', 'from the trial personnel: \"Have you had any health problems since the previous visit or since', \"you were last asked?', or revealed by observation will be collected and recorded in the eCRF.\", 'When collecting AEs, the recording of diagnoses is preferred (when possible) to recording a', 'list of signs and symptoms. However, if a diagnosis is known and there are other signs or', 'symptoms that are not generally part of the diagnosis, the diagnosis and each sign or', 'symptom will be recorded separately.', 'Any SAE, including death due to any cause, which occurs during this trial after signature of', 'the ICF, whether or not related to the IMP, must be reported immediately (within 24 hours of', \"the trial site's knowledge of the event). All SAEs will be recorded (within 24 hours) on the\", 'paper SAE Report Form and the AE form in the eCRF, the Investigator or delegated site staff', 'should check that all entered data is consistent. An alert email for the SAE report in the eCRF', \"will then automatically be sent by email to the Sponsor's designated CRO safety mailbox via\", 'the electronic data capture (EDC) system. The paper SAE Report Form should be faxed or', \"emailed to the Sponsor's designated CRO (see the Safety Mailbox/Fax details on the title\", 'page of this protocol).', 'The report will contain as much available information concerning the SAE to enable the', 'Sponsor (or an authorized representative) to file a report, which satisfies regulatory reporting', 'requirements. These timelines apply to initial reports of SAEs and to all follow-up reports.', 'Criteria for documenting the relationship to IMP as well as severity, outcome, and action', 'taken will be the same as those previously described.', 'The Investigator shall report within 24 hours any SAE (s)he becomes aware of after a', \"patient's last visit if a causal relationship with the investigational product is suspected. Such\", 'argenx BVBA', 'Confidential', 'Page 81 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'a serious adverse reaction (SAR) is to be collected and reported as previously described for', 'SAEs.', 'Additional follow-up information should be completed and entered on a paper SAE Report', \"Form and sent by fax/email to the Sponsor's designated CRO.\", '7.2.1.3. Reporting of Serious Adverse Events to Regulatory Authorities and', 'Investigators', \"The Sponsor's designee will be responsible for reporting all SUSARs, the Analysis of\", 'Similar Events (AOSE), and any other applicable reports to regulatory authorities, ethics', 'committees, and Investigators, in accordance with national regulations in the countries where', 'the trial is conducted. Relative to the first awareness of the event by/or further provision to', \"the Sponsor's designee, SUSARs will be submitted within 7 days for fatal and life-\", 'threatening events and 15 days for other SUSARs, unless otherwise required by national', \"regulations. The Sponsor's designee will also prepare an expedited report for other safety\", 'issues where applicable.', 'The investigational site will also forward a copy of all expedited reports to his or her', 'IRB/IEC in accordance with national regulations.', '7.2.1.4. Follow-up of Adverse Events and Serious Adverse Events', 'Any AEs observed from signing the ICF to the EoS visit will be followed up to resolution,', 'until the patient is lost to follow-up, or until the patient withdraws consent. Resolution means', 'that the patient has returned to a Baseline state of health or the Investigator does not expect', 'any further improvement or worsening of the AE.', 'Every effort should be made to follow all (S)AEs considered to be related to IMP or trial', 'procedures until an outcome can be reported. If the patient is lost to follow-up, all AEs will', \"be categorized based on the Investigator's last assessment.\", 'All SAEs that are spontaneously reported after the EoS visit are to be collected and reported', 'as previously described (as per Section 7.2.1.1) and will be followed up. During the trial', 'period, resolution of SAEs (with dates) should be documented on the SAE page of the eCRF', \"and in the patient's medical record to facilitate source data verification. If, after follow-up,\", 'return to the Baseline status or stabilization cannot be established, an explanation should be', 'recorded on the SAE page of the eCRF.', 'All pregnancies reported during the trial should be followed until pregnancy outcome.', \"For SAEs, non-serious AEs, and pregnancies, the Sponsor's designee may follow-up by\", 'telephone, fax, electronic mail, and/or a monitoring visit to obtain additional case details and', 'outcome information (e.g., from hospital discharge summaries, consultant reports, or autopsy', 'reports) in order to perform an independent medical assessment of the reported case.', 'argenx BVBA', 'Confidential', 'Page 82 of 110']\n\n###\n\n", "completion": "END"}